New Mission, New Website coming soon! Learn more now.

Equities logo
Search
Close this search box.

Synlogic Shows Positive Interim Phase 1/2a Data in Phenylketonuria (PKU)

Candidate shows statistically significant dose-dependent effects on biomarkers, supporting further development.